Clozapine Bl	ood Results Monitoring System	n Recommended Action					
Green Range	WBC greater than 3.5 x 10°/L AND Neutrophils greater than 2.0 x 10°/L	Continue clozapine therapy					
Amber Range	WBC 3.0 - 3.5 x 10 ⁹ /L AND/OR Neutrophils 1.5 - 2.0 x 10 ⁹ /L	Continue clozapine therapy with twice-weekly blood tests until return to "green" range					
Red Range	WBC less than 3.0 x 10 ⁹ /L AND/OR Neutrophils less than 1.5 x 10 ⁹ /L	Stop clozapine therapy immediately. Contact haematologist and Clozapine Monitoring Centre					

Recommencing Therapy after Interruption

Dosing recommendations if clozapine dose is missed for > 48 hours

- Obtain psychiatric review prior to recommencing clozapine
- Recommence at 12.5mg once or twice daily on the first day. If this dose is tolerated, it may be feasible to titrate the dose to the therapeutic level more quickly than is recommended for initial treatment.
- This is a guide only for further dosing options refer to treating psychiatrist.

	Blood Test Monitoring after Interruption of Therapy											
Monitoring frequency	Clozapine missed for < 72 hours	Clozapine missed > 72 hours but less than 4 weeks	Clozapine missed > 4 weeks									
Weekly	No change in monitoring	Monitor weekly for at least 6 weeks or for as long as necessary to achieve a total of 18 weeks of weekly monitoring	Recommence as for a new patient									
Monthly		Monitor weekly for 6 weeks then continue with monthly monitoring if no problems detected										

Side-effect	Signs and symptoms	Recommended Action
Neutropenia/ agranulocytosis	WBC < 3.0 x 109/L or Neutrophils < 1.5 x 109 /L. Flu-like symptoms such as sore throat & fever. (First 18 weeks – but may occur at any time)	Contact doctor. Stop clozapine. Contact haematologist at Clozapine Monitoring Centre.
Myocarditis/ cardiomyopathy	Fast or irregular heart beat at rest with rapid breathing, dyspnoea, hypotension, raised jugular venous pressure, fatigue, flu-like symptoms, chest pain or fever. (Cardiomyopathy may occur at any time. Myocarditis – within 6-8 weeks of starting)	Contact doctor and team. Withhold Clozapine. Repeat ECG and echocardiogram. Refer to cardiologist. If confirmed contact cardiologist at clozapine monitoring centre.
Fever	> 38° C (First 3 weeks)	Contact doctor. Reduce rate of dose titration of clozapine. Check FBC, WCC, Creatine Kinase, ECG and Echo. DO NOT give paracetamol until doctor notified and agranulocytosis / myocarditis excluded.
Seizures	Increases with high doses, rapid dose titration, concurrent use of drugs that lower seizure threshold and preexisting seizure disorders and concurrent illness. (May occur at any time.)	Contact doctor. Reduction in dose. Check with pharmacist for pharmacological options. Risk of seizures increases with higher plasma levels. Check plasma levels.
Hypersalivation	Excessive drooling – Very troublesome at night. (First few months)	Contact doctor. Check with pharmacist for pharmacological options.
Constipation	Less frequent bowel motions, hard stools, abdominal bloating, cramping or pain, decrease appetite or fatigue. (Usually persists)	Contact doctor. Recommend increased fluid intake and exercise. Treat like opioid-induced constipation, use osmotic laxatives and stimulants.
Nocturnal enuresis	Loss of bladder control, especially at night (bedwetting). (May occur at any time)	Contact doctor. Avoid fluids after 7pm. Check males for other causes. Continence referral. Check with pharmacist for pharmacological options.
Weight gain	Usually during the first years of treatment.	Dietary counselling before weight gain occurs is essential.
Nausea	First 6 weeks	May give antiemetic. Avoid prochlorperazine and metoclopramide if previously experienced Extra Pyramidal Side Effects (EPSE).

This is not an exhaustive list of side effects. Please see product information for further advice. It is recommended that concurrent use of antipsychotic therapy be avoided where possible as this increases the patient's risk of side-effects.

WA Health acknowledges contributions from Queensland Health Medication Management Services in the development of this chart. Page 4 of 4

This chart must be used under the supervision of a psychiatrist.

Please use ID label or block print

CLO		SPII	TAL	NAI	ME					Ist	JRN.	AME											UM	1RN			SE	X
	ZAF	INI	E II	ПΙ	ΓΙΑ	TI	ON	1								N(Т	ДΙ	/AL	ID								
AND										FC	DRE	NAM	ES			CF	RIP	TIC	N	UN			BIF	RTH	DAT	Έ		
	Atta	ch A	np (Stick	kor					IDENTIFIERS PRESENT																		
	Alla	CH A	DK 8	Suci	ker					PA	ATIE	NT'S	AD!	DRE	SS													
ALLERGIES Nil Known																												
Drug (or other)	OTIKITOW		eactio			omplei	te deta	Sig		First prescriber to print patient name and check label correct:																		
										First prescriber to print patient name and check label correct:																		
Sign	Drint					Dot	to.			w	Ward/Unit Consultant																	
r	pplicable box:										ui ui								,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	····	_							
☐ Initiating (c				mm	enc	eme	ent s	cre	en)		Rec	omr	nen	cing	afte	er in	terrı	uptio	n of	less	tha	n 28	da	у		Con	tinui	ing
												nce				ree	n											
Pre-comm	ence	mer	nt S	cre	en	is	req	uir	ed	to I	be (con	npl	ete	d:			Ö,	Yes									
All sections be			e co	mple	eted	prio	or to	ClOZ	apir	ne in	itiat	ion c	or wh	ien (cloza	apin	e ha	s be	en d	isco	ntinu	ied 1	or 3	3 mc	onth	s or	mor	e.
Medical Hi Patient has	_	,	auai	toly	trio	llod	lon	2 0	r m	oro	oth	or o	ntin	cv.c	hoti	icc			lo.		ΠY	/oc						
				-										-					NO			C S						
Patient has		\mathbf{T}						_																				
	as a personal or family history of cardiovascular disease No Yes Details																											
	as a history of epileptic seizures No Yes Details																											
Clozapine Psychi				ınlo t	had	and	l rot	urn	<u>م</u> ط (^l^-	zani	ne [Q_^	ictr	atio	n E	٦rm	for	Nov	,, D,	ation	nte t	o o	nh	arm	naci	ct	
☐ PBS el			COIII	ibiei	leu	anu	116	uiii	eu (J102	Δαμι	iie i	reg	1511	aliO	11 1	ווווכ	101	INCV	V F c	aucı	ilo i	u a	μΠ	alli	iaci	δι	
Contin	uatior	of s	upp	ly a	t a	regi	iste	red	clo	zapi	capine centre has been considered																	
☐ Patient	t/care	r/tam r/fam	illy r ilv h	าas เลร t	VIE\	wed n nr	CIC	zap ded	oine with	Patient Notification Form the Consumer Medication Information and the treatment explained cond opinion obtained (if applicable)																		
Patient	t has	giver	ı İnf	orm	ed (con	sen	t or																				
All Pre-Clozapine Baseline Tests have b									en performed within 10 days before clozapine commencement																			
Consultant Name:									be	en p	perf	orm	ed y	with	ine c	0 d	ays	bet	ore	cloz	zapi	ne d	com	nme	enc	eme	ent	
Consultant N	Name	•	е Ва	iseli	ine	Tes	ts h	ave	be	en p	oerf	orm Sigr	ed <u></u>	with	ned iin 1	0 d	appii ays	bet	fore	cloz	zapi		or Da		enc	eme	ent	
		:							be	en p	oerf	orm Sigr	ed <u>:</u> natu	with ire:	<u>iin</u> 1	0 d	ays	bet	fore				Da	te:				
Monitorinç Day 1 Te]: Ref	er to	hosp	oital p	proc	edui	re. \	Whe	re the	en p	oerf una sure	orm Sigr availa hour	ed y natu able ly fo	with ire: the r the	in 1	0 d	ays g are	e rec	omm	end	ed m	nonit	Date oring	te: g gu	uide e firs	lines	i.	rs
Monitoring]: Ref	er to	hosp	oital p	proc	edui	re. \	Whe	re the	en p	oerf una sure	orm Sigr availa hour	ed y natu able ly fo	with ire: the r the	in 1	0 d	ays g are	e rec	omm	end	ed m	nonit	Date oring	te: g gu	uide e firs	lines	i.	rs
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse	Ref mperat mpera	er to ture, r	hosp espir espi	oital pration	proc ns, p ns, _l	edui oulse puls	re. \ e and e an	Whe d blo	e be ere the	en press	una sure ssure	Sigr Sigr availa hour e take	natuable ly fo	with Ire: the r the vice	in 1 follo first dail	o d wing t six y or	ays are hou mor	rec rs, th	omm en e	end very	ed m six h	nonit nours icall	Date or ing serior of the seri	te: g gu the quir	uide e firs ed.	lines	i. hour	
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations	D: Ref mperat mpera rvati during	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ns, p	edui oulse pulse	re. \ e and e an	Whe d blo	e be ere the	en press	una sure ssure	Sigr Sigr availa hour e take	natuable ly fo	with Ire: the r the vice	in 1 follo first dail	o d wing t six y or	ays are hou mor	rec rs, th	omm en e	end very	ed m six h	nonit nours icall	Date or ing serior of the seri	te: g gu the quir	uide e firs ed.	lines	i. hour	
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations Key: Temp- Black	Ref mperat mperat rvati during	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ns, p of th	edui oulse pulse pulse	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with Ire: the r the vice	follo first dail	wing t six y or	ays are hou mor	e recens, the	omm en e	nend every ntly i	ed m six h f clin	nonit nours icall	Date or ing some of the sound o	te: g gu the quir	uide firs ed.	lines t 24	i. hour	art
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations Key: Temp-Black Pulse -Red	D: Ref mperat mpera rvati during	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be ere the	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations Key: Temp-Black Pulse -Red Date	Ref mperat mperat rvati during	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ns, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recens, the	omm en e	nend every ntly i	ed m six h f clin	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	i. hour	nart
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations Key: Temp- Black Pulse -Red Date Time Temp Pulse	Ref mperat mperat rvati during	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations Key: Temp- Black Pulse -Red Date Time	Ref mperat mperat rvati during	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations Key: Temp-Black Pulse -Red Date Time Temp Pulse Write ≥39.5 ≥140	Ref mperat mperat rvati during	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations Key: Temp- Black Pulse -Red Date Time Temp Pulse Write ≥39.5 ≥140 39.0-39.4 130s	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Day 1 Tel	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Ter Day 2 to 7 Ter Initial Obse Observations Key: Temp- Black Pulse -Red Date Time Temp Pulse Write ≥39.5 ≥140 39.0-39.4 130s 38.5-38.9 120s 38.0-38.4 110s	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Tel Day 2 to 7 Tel Initial Obse Observations Key: Temp- Black Pulse -Red Date Time Temp Write ≥39.5 ≥140 39.0-39.4 130s 38.5-38.9 120s 38.0-38.4 110s 37.5-37.9 100s 37.0-37.4 90s 36.5-36.9 80s	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Ter Day 2 to 7 Ter Initial Obse Observations of Key: Temp- Black Pulse -Red Date Time Temp Write ≥39.5 ≥140 39.0-39.4 130s 38.5-38.9 120s 38.0-38.4 110s 37.5-37.9 100s 37.0-37.4 90s 36.5-36.9 80s 36.0-36.4 70s	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Ter Day 2 to 7 Ter Initial Obse Observations of Key: Temp- Black Pulse - Red Date Time Temp Write ≥39.5 ≥140 39.0-39.4 130s 38.5-38.9 120s 38.0-38.4 110s 37.5-37.9 100s 37.0-37.4 90s 36.5-36.9 80s 36.0-36.4 70s 35.5-35.9 60s	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	n art
Monitoring Day 1 Ter Day 2 to 7 Ter Initial Obse Observations of Key: Temp- Black Pulse - Red Time Temp Write ≥39.5 ≥140 39.0-39.4 130s 38.5-38.9 120s 38.0-38.4 110s 37.5-37.9 100s 37.0-37.4 90s 36.5-36.9 80s 36.0-36.4 70s 35.5-35.9 60s 35.0-35.4 50s	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	n art
Monitoring Day 1 Ter Day 2 to 7 Ter Initial Obse Observations of Key: Temp- Black Pulse -Red Date Time Temp Write ≥39.5 ≥140 39.0-39.4 130s 38.0-39.4 110s 37.5-37.9 100s 37.5-37.9 100s 37.0-37.4 90s 36.5-36.9 80s 36.0-36.4 70s 35.5-35.9 60s 35.0-35.4 50s Write ≤35.0 ≤40s Blood Pressure	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring Day 1 Ter Day 2 to 7 Ter Initial Obse Observations of Key: Temp- Black Pulse -Red Date Time Temp Pulse Write ≥39.5 ≥140 39.0-39.4 130s 38.5-38.9 120s 38.0-38.4 110s 37.5-37.9 100s 37.0-37.4 90s 36.5-36.9 80s 36.0-36.4 70s 35.5-35.9 60s 35.0-35.4 50s Write ≤35.0 ≤40s Blood Pressure (Standing)	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Monitoring	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	n art
Monitoring Day 1 Ter Day 2 to 7 Ter Initial Obse Observations of Key: Temp- Black Pulse -Red Date Time Temp Write ≥39.5 ≥140 39.0-39.4 130s 38.0-38.4 110s 37.5-37.9 100s 37.0-37.4 90s 36.0-36.4 70s 35.5-35.9 60s 35.0-35.4 50s Write ≤35.0 ≤40s Blood Pressure (Standing) Blood Pressure (Lying) Respiratory Rate	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart
Day 1 Tel	nperatervation	er to ture, r ture, r ons	hosprespirespirespirespirespirespirespires	oital pration ratio	proc ns, p ons, p of th	edui pulse pulse pulse e):	re. \ e and e an	When blood blood	e be	en press	una sure sure	Sigravaila hour e take	natuable ly fo en to	with ure: the r the vice	follo first dail	wing six y or	ays are hou mor	e recense, the	omm en e	nend every ntly i	ed m six h f clin erva	nonit nours ically tion	Date oring soften for the control of	te: g gu the quir	uide e firs ed.	lines t 24	hour	nart

U=Unresponsive)

BARCODE AREA

11/17

HCHxxxxxxxx Page 1 of 4

HOSPITAL NAME

CLOZAPINE INITIATION AND TITRATION CHART

Please use ID label or block print										
SURNAME	UMRN	SEX								
NOT A VALID										
FORENAMES PRESCRIPTION UNLESS	BIRTHDATE									
IDENTIFIERS PRESENT										
PATIENT'S ADDRESS										

Page 2 of 4

Year	20	

Clozapine Dose Orders

<u>DO NOT</u> prescribe clozapine until approved by Clozapine Monitoring Centre and Patient Clozapine Number allocated. Commence clozapine in the morning to allow hourly monitoring for the first six hours.

Pharmacy use:	Medica	tion C	lozapine	Formul	lation:	Patient Clozapine Number:								
Date Date	Route:	oral		Indication:		1								
test due										until :				
(PRINT) 08:00hr Nurse 1/ Nurse 2 1 2 2 2 2 3 3 4 4 4 5 5 6 6 6 6 6 6 6 6	Date	Day						Night dose		Drug level	Pharmacy			
1				(PRINT)	o.g.iata.o	08:00hr	Nurse 1/	20:00hr						
2 3 3 4 4 4 5 5 6 6 6 7 7 7 8 8 8 9 9 10 10 11 1 11 1 1 1 1 1 1 1 1 1 1 1							Nurse 2		Nurse 2					
3 4 4 5 5 6 6 7 7 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9		1												
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27		2												
5 6 7 8 8 9 10 11 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 27		3												
6 7 7 8 8 9 9 10 10 11 11 12 12 13 13 14 14 15 15 16 16 17 17 18 18 19 19 19 19 19 19 19 19 19 19 19 19 19		4												
7		5												
8 8 9 9 10 10 11 11 12 12 13 13 14 14 15 15 16 16 17 17 18 18 19 19 19 19 19 19 19 19 19 19 19 19 19		6												
9		7												
10		8												
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27		9												
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27		10												
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27		11								4				
14 15 16 17 18 19 20 21 22 23 24 25 26 27		12								7				
15 16 17 18 19 20 21 22 23 24 25 26 27		13												
16 17 18 19 20 21 22 23 24 25 26 27		14												
17 18 19 20 21 22 23 24 25 26 27		15												
18 19 20 21 22 23 24 25 26 27		16												
19 20 21 22 23 24 25 26 27		17												
20 ————————————————————————————————————		18												
21 22 23 24 25 26 27		19												
22 23 24 25 26 27		20												
23 24 25 26 27		21												
24 25 26 27		22												
25 26 27 27 27 28 29 29 29 29 29 29 29 29 29 29 29 29 29		23												
26 27		24												
27		25												
		26												
28		27												
		28												

	Clozapine Dose Titration Schedule													
Patients Titration	This table serves as a guide only and dose titration should be individualised. Patients > 65 years of age may require a slower dose increase titration regimen. Titration beyond 200mg/day : If well tolerated, the daily dose may be increased slowly in increments of 25-50mg (maximum 100mg/week).													
Day	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Morning	12.5mg	25mg	50mg	50mg	50mg	50mg	50mg	50mg						
Evening				25ma	25ma	50ma	75ma	100ma	100ma	100ma	125mg	125ma	125ma	150ma

	Monitoring Che	cklist –	Baseline l	Measurem	ents Whe	n Comme	ncing Clo	zapine	
Blood	group	Hei	ght	m	Smoking s	status: 🗌 Smo	oker 🗌 Non	Smoker	
	Intervals	Pre-cloza baseline	pine	Day 7	Day 14	Day 21	Day 28	After 28 days	
	intervale	Date	Results	Date:	Date:	Date:	Date:	7 iitoi 20 dayo	
by cian	Full physical exam (To be completed by doctor)		Performed					Annually	
eted dieti	Dietician review		Performed					7 unidany	
To be completed by doctor/ nurse/ dietician	Weight		kg						
be constant	Waist		cm					Monthly	
) pop	BMI weight (kg)/ height (m²)								
	Full Blood Count		Performed	Performed	Performed	Performed	Performed		
	White Blood Count		x10 ⁹ /L	Weekly first 18 weeks - then every 28					
	Neutrophils Absolute		x10º/L	x10 ⁹ /L	x10 ⁹ /L	x10 ⁹ /L	x10 ⁹ /L	days	
	Eosinophils Absolute		x10º/L	x10 ⁹ /L	x10 ⁹ /L	x10 ⁹ /L	x10 ⁹ /L		
	Liver function test		Performed					6 monthly	
or	Urea & Electrolytes		Performed					6 monthly	
Doct	Fasting plasma glucose		mmol/L						
To be completed by Doctor	Total cholesterol (fasting)		mmol/L						
nplet	LDL (fasting)		mmol/L					6 monthly	
oe cor	HDL (fasting)		mmol/L						
To b	Triglycerides (fasting)		mmol/L						
	Troponin		micrgrams/L	micrgrams/L	micrgrams/L	micrgrams/L	micrgrams/L	When needed	
	C-Reactive Protein (CRP)		mg/L	mg/L	mg/L	mg/L	mg/L	When needed	
	ECG (QT interval)							6 monthly	
	Cardiac echocardiogram							At 6 months- then annually	
	Beta HCG (female)							When needed	
These	are suggested guidelines o	only, refer to	the treating psy	chiatrist for indi	vidual monitorin	g requirements			

	Reason For Not Administering (codes must be circled)												
Absent	A	On Leave (D	Refused-notify doctor	R	Vomiting – notify doctor	V						
Fasting	F	Not Available - obtain Supply and/or notify doctor, consider incident report	N)	Withheld-enter reason in clinical record	w	Self- Administering – observed or claimed	S						

Page 3 of 4